Skip to main content
News Icon

News categories: Honors & Funding

Patent-Prize awarded for programing of stem cells into Photoreceptors

Discovery and utilization of three different transcription factors enables the directed differentiation of human stem cells into photoreceptors

Prof. Volker Busskamp, Member of the Cluster of Excellence ImmunoSensation2, is awarded with the Patent-Prize of the German Ophthalmological Society for his work on photoreceptors. The Biotechnologist and his team developed a technology, which allows the rapid programming of human stem cells to become photoreceptors. The resulting cells are used in retinal research and shall serve in clinical application to treat blindness in the near future.

Photoreceptors are sensory cells of the eye, located in the retina. They enable seeing by detection of the incoming light and its translation into electrochemical signals. Degeneration or loss of photoreceptor cells, as in macular degeneration, retinitis pigmentosa or retinal detachment, leads to vision impairment or even blindness.

Volker Busskamp and his team established a reliable method to quickly generate photoreceptor cells, which was now awarded with the Patent-Prize of the German Ophthalmological Society. The award honors inventions with patent pending and supports outstanding concepts in Ophthalmology.

The awarded method is based on the discovery and utilization of three different transcription factors, which induce the differentiation of human stem cells into photoreceptors. In the Petry-dish, the cells grow into light-sensitive receptor cells within several days. The method allows for the generation of vast amounts of cell material. This is of particular relevance, as the retina itself does not possess any regenerative potential. The possibility to generate human photoreceptors in the Petry-dish hence opens new prospects in basic research, drug screening, but also clinical application: The possible utilization of the photoreceptors in photoreceptor-replacement therapy is already under investigation.

Prof. Busskamp and his team are involved in the technology transfer supported by a ‘proof-of-concept’ grand of the European Research Council. In the end, a biomedical application of human stem cells programmed into photoreceptors is supposed to be part of an innovative therapy to treat all sorts of photoreceptor-degeneration associated diseases.


Contact

Prof. Dr. Volker Busskamp

Universitäts-Augenklinik Bonn

Tel.: +49 228 287-13687

E-Mail: volker.busskamp(at)ukbonn.de


Related news

Prof. Dr. Frank G. Holz – Director of the Department of Ophthalmology at the University Hospital Bonn (UKB) and Professor at the University of Bonn.

News categories: Honors & Funding

Frank Holz Nominated for the Science Breakthrough of the Year 2026

A remarkable achievement for the Faculty of Medicine at the University of Bonn: Prof. Dr. Frank G. Holz, Director of the Department of Ophthalmology at the UKB and Professor at the University of Bonn, has been shortlisted for the Falling Walls Science Breakthrough of the Year 2026 in the Life Sciences category. His project is now among the 30 most outstanding scientific innovations worldwide in this category, recognized by the prestigious Falling Walls Science Summit. Being shortlisted alone represents a significant international distinction.
View entry
Prof. Dr. Elvira Mass (left) and Prof. Dr. Tatjana Tchumatchenko (right)

News categories: Honors & Funding

Hunting for New Angles

New research questions often arise where different methods, mindsets and subject-specific cultures meet, and it is these kinds of encounter that Professor Elvira Mass and Professor Tatjana Tchumatchenko want to make happen in a targeted way in future. The two researchers have been picked as Henriette Herz Scouts by the Alexander von Humboldt Foundation.
View entry
Precise Konsortium

News categories: Publication Honors & Funding

Making Cancer Cells More Predictable: PRECISE Aims to Forecast Therapeutically Actionable Vulnerabilities

Which genes and signaling pathways does a cancer cell require to survive? And which of these could serve as therapeutic targets? The pan-European initiative PRECISE aims to identify such vulnerabilities not only through labor-intensive laboratory experiments but also by predicting them using computational models. The UKB and the University of Bonn, represented by Prof. Dr. Maximilian Billmann and Prof. Dr. Jonathan Schmid-Burgk, are among the founding partners of the consortium. The scientific vision of the initiative has now been published in a commentary in Nature Genetics.
View entry

Back to the news overview